Dinutuximab beta binds GD2 on tumor cells; its Fc engages Fcγ receptors (including CD16b/FCGR3B) on immune effector cells to trigger ADCC/phagocytosis and complement-mediated lysis of GD2+ cells. FCGR3B-expressing cells are not targeted or killed by the drug.